Exelixis ((EXEL)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Study Overview: The clinical study titled ‘A Phase 1b/2 Study of Immune and Targeted Combination Therapies in Participants With RCC (KEYMAKER-U03): Substudy 03C’ aims to evaluate the safety and efficacy of experimental drug combinations in patients with clear cell renal cell carcinoma (ccRCC) who have experienced recurrent disease during or after anti-PD-(L)1 therapy. This study is significant as it explores new treatment avenues for a challenging cancer type.
Intervention/Treatment: The study tests two experimental drug combinations: Zanzalintinib at two different dose levels combined with Belzutifan. These drugs are administered orally and are intended to manage ccRCC by halting disease progression.
Study Design: This interventional study is non-randomized with a parallel assignment model. It employs single masking, where the outcomes assessor is blinded. The primary purpose is treatment-focused, with an initial safety lead-in phase followed by an efficacy phase.
Study Timeline: The study began on June 25, 2025, with the latest update submitted on August 18, 2025. These dates are crucial as they mark the study’s initiation and the most recent information available, indicating its ongoing status.
Market Implications: The study’s progress could positively influence Exelixis’s stock performance, as successful results may enhance their competitive edge in the oncology market. Investors should monitor updates closely, as advancements in treatment efficacy could shift market dynamics and investor sentiment.
The study is currently recruiting, with further details accessible on the ClinicalTrials portal.